Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness

Molecular Vision

Volumn 15, Issue , 2009, Pages 1906-1914

  Ozturk, Banu Turgut ^a   Bozkurt, Banu ^a   Kerimoglu, Hurkan ^a   Okka, Mehmet ^a   Kamis, Umit ^a   Gunduz, Kemal ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; HEMOGLOBIN A1C; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VISUAL ACUITY;

CHEMOKINE CCL2; CYTOKINES; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MACULA LUTEA; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 70349609915     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Klein R, Klein BEK, Moss SE, Davis MD, Demets DL. The Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology 1984; 91:1464-74.
2. Clark JB, Grey RH, Lim KK, Burns-Cox CJ. Loss of vision before ophthalmic referral in blind and partially sighted diabetics in Bristol. Br J Ophthalmol 1994; 78:741-4.
3. Perkovich BT, Meyers SM. Systemic factors affecting diabetic amcular edema. Am J Ophthalmol 1988; 105:211-2.
4. Klein R, Moss SE, Klein BE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XI. The incidence of macular edema. Ophthalmology 1989; 96:1501-10.
5. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol 2009; 54:1-32.
6. Meyer CH. Current treatment approaches in diabetic macular edema. Ophthalmologica 2007; 221:118-31.
7. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002; 86:363-5.
8. Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 2006; 82:798-806.
9. Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 2006; 17:155-65.
10. Hernández C, Sequra RM, Fonollosa A, Carrasco E, Francisco G, Simo R. Interleukin - 8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005; 22:719-22.
11. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000; 243:243-55.
12. Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 2005; 66:175-91.
13. Ray CA, Bowsher RR, Smith WC, Devanarayan V, Willey MB, Brandt JT, Dean RA. Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J Pharm Biomed Anal 2005; 36:1037-44.
14. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110:1677-82.
15. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H, Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 2008; 115:1366-71.
16. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122:477-85.
17. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent DM. N Engl J Med 1993; 329:977-86.
18. Moore J, Bagley S, Ireland G, McLeod D, Boulton ME. Three dimensional analysis of microaneurysms in the human diabetic retina. J Anat 1999; 194:89-100.
19. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 2001; 15:257-9.
20. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, Savli H. Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 2002; 16:163-70.
21. Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Wedrich A, Theisl A, Aigner R, Barth A, Haas A. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis 2008; 14:637-43.
22. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101:1219-24.
23. Minchenko A, Salceda S, Bauer T, Caro J. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 1994; 40:35-9.
24. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997; 64:505-17.
25. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. Vascular Enodthelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema. Am J Ophthalmol 2006; 142:961-9.
26. Cavusoglu AC, Bilgili S, Alaluf A, Dogan A, Yilmaz F, Aslanca D, Karaca B, Yüksel B, Topaloglu E. Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy. Ann Ophthalmol (Skokie) 2007; 39:205-8.
27. Petrovic MG, Korosec P, Kosnik M, Osredkar J, Hawlina M, Peterlin B, Petrovic D. Local and Genetic Determinants of Vascular Endothelial Growth Factor Expression in Advanced Proliferative Diabetic Retinopathy. Mol Vis 2008; 14:1382-7.
28. Meleth AD, Agron E, Chan C, Reed GF, Arora K, Byrnes G, Csaky KG, Ferris FL III, Chew EY. Serum Inflammatory Markers in Diabetic Retinopathy. Invest Ophthalmol Vis Sci 2005; 46:4295-301.
29. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271:736-41.
30. Maruo N, Morita I, Shirao M, Murota S. IL-6 increases endothelial permeability in vitro. Endocrinology 1992; 131:710-4.
31. Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci 2008; 38:361-7.
32. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995; 14:1045-53.
33. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukkaruppan V. Proinflammatory Cytokines and Angiogenic and Anti-angiogenic Factors in Vitreous of Patients with Proliferative Diabetic Retinopathy and Eales Disease. Retina 2008; 28:817-24.
34. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and antiinflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dryeye disease. Invest Ophthalmol Vis Sci 2001; 42:2283-92.
35. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11:165-90.
36. Taub DD. Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev 1996; 7:355-76.
37. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169:1485-90.
38. Jo N, Wu GS, Rao NA. Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2003; 44:4054-60.
39. Takaishi H, Taniguchi T, Takahashi A, Ishikawa Y, Yokoyama M. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res Commun 2003; 305:122-8.
40. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica 2001; 215:415-8.
41. Scannell G, Waxman K, Kaml GJ, Ioli G, Gatagana T, Yamamoto R, Granger GA. Hypoxia induces a human macrophage cell line to release tumor necrosis factor-alpha and its soluble receptors in vitro. J Surg Res 1993; 54:281-5.
42. Yoshida S, Yoshida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1and MIP-1 alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol 2003; 73:137-44.
43. Hanifi-Moghaddam P, Kappler S, Seissler J. Müller-Scholze S, Martin S, Roep BO, Strassburger K, Kolb H, Schlott NC. Altered chemokine levels in individuals et risk of Type 1 diabetes mellitus. Diabet Med 2006; 23:156-63.
44. Capeans C, De Rojas MV, Lojo S, Salorio MS. C -C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998; 18:546-50.
45. Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis-Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B. Intravitreal growth factors in proliferative diabetic retinopathy: Correlation with neovascular activity and glycaemic management. Br J Ophthalmol 1997; 81:228-33.
46. McAvoy JW, Chamberlain CG. Growth factors in the eye. Prog Growth Factor Res 1990; 2:29-43.
47. Patel B, Hiscott P, Charteris D, Mather J, McLeod D, Boulton M. Retinal and preretinal localisation of epidermal growth factor, transforming growth factor alpha, and their receptor in proliferative diabetic retinopathy. Br J Ophthalmol 1994; 78:714-8.
48. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116:73-9.
49. Navarro-González JF, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19:433-42.
50. Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005; 366:2058-61.